12.8 C
London

Mesothelioma

Bayer antibody-drug conjulate (ADC) misses in phase 2 mesothelioma trial

Bayer antibody-drug conjulate (ADC) misses in phase 2 mesothelioma trial
Bayer's antibody-drug conjulate (ADC) anetumab ravtansine has failed to show improvements in the survival rates of mesothelioma patients. Stock prices of Bayer's collaborators ImmunoGen and MorphoSys declined as the announcement was made. Malignant pleural mesothelioma is a rare cancer that affects more than 25,000 people around the world. Around 15,000 new cases are seen every...

LATEST